The newly approved RSV vaccine could be rolled out by fall 2023, in time for the typical winter surge in RSV infections.
Academic rigor, journalistic flair
Articles on Pfizer
Displaying 1 - 20 of 111 articles
The CDC’s endorsement of the reformulated COVID-19 booster shots represents a major step in the effort to get more Americans boosted.
Early on, public health messaging focused on the need for vaccines to combat COVID-19. But far less attention has been given to the role of boosters in preventing deaths and reducing inequities.
We hear a lot about drug-resistant bacteria. The same thing can happen with viruses.
It’s natural to have questions about the risks and benefits of COVID vaccines in young children. Here’s what you need to know ahead of Australia’s rollout.
Is it time for a new generation of COVID vaccines? Here’s where the research is at.
On the horizon: A new omicron-focused version of the Moderna vaccine that may offer longer protection and a stronger immune response.
Waiving patent rights on COVID-19 vaccines and drugs is still crucial to ensure access globally, but the waiver on the table at the June World Trade Organization meeting doesn’t do the job.
Boosters and vaccinating children mean we’re relying on two pharmaceutical companies to supply Australia’s COVID vaccines. That needs to change.
The COVID-19 pandemic has brought immunology terms that are typically relegated to textbooks into our everyday vernacular. These stories helped us make sense of the ever-evolving science.
Fewer people reported needing to miss work after their booster, compared to their second dose.
Both companies say their drugs will work against the Omicron variant, though this is based on preliminary, lab-based research.
We’re reliant on overseas supply - and the many moving parts of delivery. Each of those parts require staff on the ground – and many workers in this system are likely being affected by Omicron.
Even with a variant like Omicron that may be more transmissible than earlier variants, vaccines remain the most effective tool for protection against COVID-19 and for ending the pandemic.
The Pfizer COVID-19 vaccine will be available for children aged 5-11 from January 10, after it cleared the final regulatory step. Here’s what you need to know.
The world needs to learn to live with the virus. And governments must follow the science and don’t distort it for political expediency.
Merck and Pfizer both have oral antiviral pills under review by the FDA. Such treatments could help turn the tide of the pandemic.
Properly engaged and monitored, Nigeria’s private sector can do more in COVID vaccination exercise.
Paxlovid is one potential COVID drug for use at home. The idea is these can potentially be prescribed at the first sign of infection to prevent serious illness and death.
The focus of the government seems to be about how many people can get vaccinated rather than ensuring the greatest protection against severe disease and deaths.
Top contributors
-
Associate Professor and ARC Future Fellow, The University of Western Australia
-
Associate Professor, Discipline of Childhood and Adolescent Health, University of Sydney
-
Dean Faculty of Health Sciences and Professor of Vaccinology at University of the Witwatersrand; and Director of the SAMRC Vaccines and Infectious Diseases Analytics Research Unit, University of the Witwatersrand
-
Professor of Medicine, University of Virginia
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Research associate, Warren Alpert Medical School, Brown University, Brown University
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Professorial Fellow, University of Canberra
-
Instructor of Human Immunology, Emory University
-
Associate Professor of the Sydney Pharmacy School, University of Sydney
-
Associate Professor of Biology, Rochester Institute of Technology
-
Paediatrician at the Royal Childrens Hospital and Associate Professor and Clinician Scientist, University of Melbourne and MCRI, Murdoch Children's Research Institute
-
Professor Emeritus of Health Policy and Management, York University, Canada
-
Vice-Chancellor's Research Fellow, School of Health and Biomedical Sciences, RMIT University
-
Professor of Global Biosecurity, NHMRC Principal Research Fellow, Head, Biosecurity Program, Kirby Institute, UNSW Sydney
